Add United States Surgeon General Doctor Jerome Adams to the list of experts advocating for the reclassification of cannabis as a Schedule 1 drug in order to ease up U.S. researchers access to the materials needed to conduct studies. The Surgeon General is one of many who believes that theRead More →
Anheuser-Busch, the makers of Budweiser, and British Columbia-based Tilray have embarked on a research partnership to the tune of $50M to research both CBD and THC for the burgeoning cannabis-infused beverage market. The announcement comes after several other prominent beer-makers have made their own moves towards the canna-beverages space. BackRead More →
Dr. Brooke J. Arterberry (Iowa State University in Ames) and colleagues have determined that onset of cannabis-use disorder (CUD) after first-use may be precipitated by the strength of the cannabis at the time of first use and further study is needed. The likelihood of progressing from cannabis initiation to aRead More →
Here’s what’s happening today in the world of CBD research, products and announcements: It’s Time To Remove Cannabis From The Federal Drug Schedules “One reason there has been so little in the United States is precisely because cannabis is listed on Schedule I, a designation that creates significant barriers toRead More →
Dr. M-J Milloy holds the inaugural post of Canopy Growth Professor of Cannabis Science at the University of British Columbia. He says there’s still so much research needed to confirm our beliefs about the effects of cannabis on human subjects. Dr. Milloy is interested to see if cannabis offers treatmentRead More →
![Evaluating the Therapeutic Potential of Cannabinoids: How to conduct research within the current regulatory framework [VIDEO]](https://www.crforum.io/wp-content/uploads/2018/12/fda-690x500.jpg)
On December 8, 2018, the following NIH-sponsored proceeding took place: “Evaluating the Therapeutic Potential of Cannabinoids: How to conduct research within the current regulatory framework“ From the website: The National Center for Complementary and Integrative Health (NCCIH), at the National Institutes of Health (NIH), sponsored a workshop on December 8,Read More →
Canada continues to lead the way in terms of applied cannabis research. The Ontario Long Term Care Association is embarking on a study of 500 seniors in the Ontario region to study the effects of cannabis use among seniors in long-term care. The outcomes of the study will inform policyRead More →
JAMA Network Open recently published a report entitled “Acute Effects of Smoked and Vaporized Cannabis in Healthy Adults Who Infrequently Use Cannabis.” The piece presented the main questions examined in the study: How does smoked and vaporized cannabis acutely influence subjective drug effects, cognitive and psychomotor performance, and cardiovascular measures inRead More →
According to a recent article in The Stranger, Seattle-based Verda Bio is the first company in the state of Washington to be issued an official license to conduct cannabis research. The company is going to focus initially on plants that produce so-called “minor cannabinoids” — lesser known compounds that occurRead More →
In spite of legalization of cannabis happening throughout much of the U.S. and full legalization in Canada, the state of medical research of cannabis is lagging behind in the United States. Legalization in other countries has paved the way for much easier access to research and standardization in the industry.Read More →